26 results
Primary Objectives1. To raise awareness and enhance the diagnosis of patients with chronic low back pain (CLBP) with a neuropathic pain component who are refractory to standard analgesic therapy and/or one treatment for neuropathic pain in a primary…
The objective of this study is to investigate, in patients with closed subcapital fractures of the fifth metacarpal, whether functional treatment leads to better or equal results compared to splinting, regarding handfunction, fracture healing,…
To evaluate the long-term safety and tolerability of pregabalin in pediatric subjects 1 month through 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with (PGTC) seizures.
Primary phase 1: To determine MTD and/or RP2D of INC280 incombination with erlotinibPrimary phase 2: To compare the antitumor activity of INC280 alone, and INC280 in combination with erlotinib, vs platinum with pemetrexed, as measured by Progression…
Primary: 1/ To determine the higher of the tolerated dose of INC280 tablets with food between 300 and 400 mg BID in patients with cMET dysregulated advanced solid tumors. 2/ To assess the PK of INC280 with food.Secondary: To assess the safety of…
The purpose of the study is to investigate the optimal dose combination of both drugs in healthy volunteers who will undergo a pain test.
The primary goal of this study is to determine if there are any benefits in addition of pregabalin and s-ketamine to local knee infiltration with ropivacaine/adrenaline/kenacort®, regarding the analgesia and the early mobilization in the study group…
Primary objectiveThe primary objective is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol PR (300 mg per day after run in, up titration to 500 mg per day) versus a combination of tapentadol PR (300 mg per…
The primary objective of this study is to evaluate the efficacy of 2 dose levels of pregabalin (Level 1: 2.5 mg/kg/day; maximum 150 mg day and Level 2: 10 mg/kg/day; maximum 600 mg day) compared to placebo as an adjunctive treatment in reducing the…
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
Determine efficiency and safety of two different doses of pregabalin as compared to placebo.
To investigate the ability of PF-05089771 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.
The primary objective is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best…
OBJECTIVESPrimary ObjectiveThe primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic peripheral neuropathy (…
The primary objective of this study is to investigate whether pregabalin at a dose of 150-600 mg twice a day reduces pain in patients with chronic neuropathic pain after herniorraphy. This research question will be answered by testing of the…
To compare efficiency, side effects and costs of a strategy with amitriptyline as drug of first choice versus a strategy with pregabalin as drug of first choice.
To investigate the ability of PF-06273340 to demonstrate analgesic properties in healthy subjects for pre-specified primary endpoints using a panel of pain tests.
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
The aim of this prospective, multicentre randomized phase II study is to evaluate the safety and efficacy of the combination of capmatinib and spartalizumab in subjects with EGFR weight (for exon 19 deletions and exon 21 L858R substitution mutations…
The main objective is to determine the change in CS parameters upon administration of tapentadol in comparison to pregabalin in patients suffering from chronic pain that has a visceral or deep somatic origin.